Skip to content

Circulating tumor cell count predicts prostate cancer survival, can help tailor treatment

Posted in News, and Research

October 07, 2024

“Prostate cancer is the most common malignancy [among] American men and the second most lethal,” Amir Goldkorn, MD, professor of medicine and biochemistry & molecular medicine at Keck School of Medicine and associate director for translational research at USC Norris Comprehensive Cancer Center, told Healio. “New drugs are emerging, but there are very few assays that can tell physicians how well a given patient will fare over time and with treatment.” View full article here.